Synthesis, biological activity screening and molecular modeling study of acylaminoacetamide derivatives
摘要:
In this study, non-rigid analogs of thalidomide have been designed in order to develop potentially active, more effective and safer lead molecules for disorders caused or contributed by inflammation. Five different series of acylaminoacetamide compounds were synthesized, and the biological inhibitory potency of the title compounds has been determined by evaluating their effects on COX-2 isoenzyme expression and PGE(2) production in A549 (human lung adenocarcinoma) cell lines. Among the studied series, N-[2-(isopropylamino)-2-oxoethyl]isonicotinamide is the most active inhibitory compound on COX-2 isoenzyme expression, and N-[2-oxo-2-(pyrolydine-1-yl)etyl]isonicotinamide is the most active inhibitory compound on the biosynthesis of PGE(2). Molecular docking studies and molecular dynamics simulations were also applied to investigate non-covalent interactions of the most active compounds inside the active side of the crystal structure of murine cyclooxygenase 2 (mCOX-2) isoenzyme.
Kyazimova; Makhmudova, Russian Journal of Applied Chemistry, 2000, vol. 73, # 8, p. 1477 - 1478
作者:Kyazimova、Makhmudova
DOI:——
日期:——
Haworth et al., Journal of the Chemical Society, 1952, p. 2972,2978
作者:Haworth et al.
DOI:——
日期:——
ZUR BEHANDLUNG VON KREBSERKRANKUNGEN GEEIGNETE 7 -AZAINDOLDERIVATE
申请人:Merck Patent GmbH
公开号:EP2723736A1
公开(公告)日:2014-04-30
KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
申请人:Imago Biosciences Inc.
公开号:EP3030323B1
公开(公告)日:2019-04-24
[DE] ZUR BEHANDLUNG VON KREBSERKRANKUNGEN GEEIGNETE 7 -AZAINDOLDERIVATE<br/>[EN] 7-AZAINDOLE DERIVATIVES SUITABLE FOR TREATMENT OF CANCERS<br/>[FR] DÉRIVÉS 7-AZAINDOLE CONVENANT AU TRAITEMENT DE MALADIES CANCÉREUSES
申请人:MERCK PATENT GMBH
公开号:WO2012175168A1
公开(公告)日:2012-12-27
Verbindungen der Formel (I) worin R1, R2 und R3 die in Anspruch 1 angegebenen Bedeutungen haben, sind Inhibitoren der PDK1 und der Zellproliferation/ Zellvitalität und können Behandlung von Tumoren eingesetzt werden.